Search results
Results from the WOW.Com Content Network
Bevacizumab, sold under the brand name Avastin among others, is a monoclonal antibody medication used to treat a number of types of cancers and a specific eye disease. [30] [28] For cancer, it is given by slow injection into a vein (intravenous) and used for colon cancer, lung cancer, ovarian cancer, glioblastoma, hepatocellular carcinoma, and renal-cell carcinoma. [31]
By May 2012, anti-VEGF treatment with Avastin has been accepted by Medicare, is quite reasonably priced, and effective. Lucentis has a similar but smaller molecular structure to Avastin, and is FDA-approved (2006) for treating MacD, yet remains more costly, as is the more recent (approved in 2011) aflibercept (Eylea). Tests on these treatments ...
Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment created from the same parent mouse antibody as bevacizumab.It is an anti-angiogenic [16] that is approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion.
In 2008, accelerated approval was granted for Avastin in combination with chemotherapy for previously untreated advanced HER2-negative breast cancer. In 2009, Avastin gained its fifth approval for treatment of glioblastoma multiforme, and sixth approval for the treatment of metastatic renal cell carcinoma. It was most publicized for its ...
The number of injections tripled to 15,000 in 2002 when triamcinolone injections were first used to treat diabetic macular oedema. [2] [3] This use continued to drive an increase to 83,000 injections in 2004. [2] In 2005 bevacizumab and ranibizumab intravitreal injections for the treatment of wet-AMD caused a rise in injections to 252,000. [2]
The dose schedule given every two weeks is as follows: [5] Day 1–2: Oxaliplatin 100 mg/m 2 IV infusion, given as a 120 minutes IV infusion in 500 mL D5W, concurrent with leucovorin 400 mg/m 2 (or levoleucovorin 200 mg/m 2) IV infusion, followed by 5-FU 400 mg/m 2 IV bolus, followed by 46-hour 5-FU infusion (2400 mg/m 2 for first two cycles, and may be increased to 3000 mg/m 2 if tolerated by ...
Vaccine combinations (few exceptions), antibiotics, low-dose steroids (less than 20 mg per day), minor infections with low fever (below 38.5º Celsius), diarrhea, malnutrition, kidney or liver disease, heart or lung disease, non-progressive encephalopathy, well controlled epilepsy or advanced age, are not contraindications to vaccination.
The Philippines has received 100,000 doses of the Sinopharm BIBP vaccine from the United Arab Emirates. [102] The Philippines has received a donation of about 1,000,000 doses of the Sinopharm BIBP vaccine on August 20–21 from China. [103] [104] The Philippines has expressed its intent to get some of Canada's COVID-19 vaccines. [105]